Search alternatives:
ppm decrease » _ decrease (Expand Search), pa decreased (Expand Search), 026 decrease (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
ht decrease » _ decrease (Expand Search), we decrease (Expand Search), step decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
5 ht » 5 h (Expand Search)
ppm decrease » _ decrease (Expand Search), pa decreased (Expand Search), 026 decrease (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
ht decrease » _ decrease (Expand Search), we decrease (Expand Search), step decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
5 ht » 5 h (Expand Search)
-
81
-
82
Respiratory network responses to systemic 5-HT<sub>2A</sub>R and 5-HT<sub>2B</sub>R activation.
Published 2013“…PNA frequency decreased below control. (<b>B</b>) Application of the 5-HT<sub>2B</sub>R agonist BW 723C86 increased PNA frequency. …”
-
83
Pharmacological Mechanism of the Non-hallucinogenic 5‑HT<sub>2A</sub> Agonist Ariadne and Analogs
Published 2022“…Compared to DOM, Ariadne shows lower signaling potency and efficacy in multiple signaling pathways examined (G<sub>q</sub>, G<sub>11</sub>, and β-arrestin2) coupled to 5-HT<sub>2A</sub> receptors. We confirmed the shift in signaling for an α-propyl analog and provide a molecular docking rationale for the progressive decrease in signaling potency with the growing length of the α-substituent. …”
-
84
Pharmacological Mechanism of the Non-hallucinogenic 5‑HT<sub>2A</sub> Agonist Ariadne and Analogs
Published 2022“…Compared to DOM, Ariadne shows lower signaling potency and efficacy in multiple signaling pathways examined (G<sub>q</sub>, G<sub>11</sub>, and β-arrestin2) coupled to 5-HT<sub>2A</sub> receptors. We confirmed the shift in signaling for an α-propyl analog and provide a molecular docking rationale for the progressive decrease in signaling potency with the growing length of the α-substituent. …”
-
85
-
86
-
87
-
88
PPM1A facilitates both nuclear distribution and transcription potency of YAP/TAZ.
Published 2021“…<b>(B–D)</b> Transcription potency of YAP (5 ng), which was suppressed by coexpression of MST1 (50 ng) (B), LATS1 (500 ng) (C), or MAP4K1 (50 ng) (D), was markedly recovered by cotransfection of wild-type PPM1A but not the enzyme-dead PPM1A (D239N). …”
-
89
-
90
Human 5-HT<sub>4</sub>-based RASSLs.
Published 2007“…Rs1.2 is Rs1 with an extra D<sup>66</sup>A mutation that decreased constitutive G<sub>s</sub> signaling. Rs1.3 is the Rs1-i3-5-HT<sub>1A</sub> chimera with G<sub>i</sub> signaling. …”
-
91
-
92
-
93
Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.
Published 2016“…<p>Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.…”
-
94
-
95
-
96
-
97
-
98
-
99
-
100